Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDK5 siRNA
- Development stage
- Unknown
- Lead developer
- Cell Signaling Technology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
CDK5 siRNA refers to a class of small interfering RNA (siRNA) molecules designed to selectively silence the expression of Cyclin-Dependent Kinase 5 (CDK5). CDK5 is a serine/threonine kinase primarily active in post-mitotic neurons, where it regulates neuronal migration and synaptic plasticity, but it is also implicated in the progression of various cancers, including glioblastoma multiforme (GBM), prostate cancer, and multiple myeloma. These siRNA reagents function by inducing the degradation of CDK5 mRNA, thereby reducing protein levels and inhibiting downstream signaling pathways, such as the phosphorylation of Drp1 at serine 616, which affects mitochondrial fission. Currently, CDK5 siRNA is utilized exclusively as a laboratory research tool for in vitro gene knockdown experiments and is not approved for clinical therapeutic use in humans.
- Brand names
- SignalSilence
- Other names
- CDK5 small interfering RNACDK-5 small interfering RNACDK 5 small interfering RNACyclin-dependent kinase 5 siRNA
02
Targets
CDK5 (Cyclin-dependent kinase 5)
Beyond the preview
Go deeper on CDK5 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDK5 siRNA.